Author

Kadalraja Raghavan

OpenAlex ID: A5077328352

Benefits of Gut Microbiota Reconstitution by Beta 1,3–1,6 Glucans in Subjects with Autism Spectrum Disorder and Other Neurodegenerative Diseases

2022 · Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, et al. · Journal of Alzheimer s Disease · 50

PDF

Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study

2021 · Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, et al. · Biomedicine & Pharmacotherapy · 39

PDF

Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomised, parallel-group pilot clinical study

2022 · Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, et al. · BMJ Neurology Open · 34

β‑glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B‑VACCIEN) in specific immunocompromised populations (Review)

2021 · Nobunao Ikewaki, Vidyasagar Dedeepiya, et al. · Oncology Reports · 25

PDF

Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential applications in human health and disease

2022 · Senthilkumar Preethy, Nobunao Ikewaki, et al. · BMJ Open Gastroenterology · 21

PDF

Improvement of sleep and melatonin in children with autism spectrum disorder after β‐1,3/1,6‐glucan consumption: An open‐label prospective pilot clinical study

2022 · Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, et al. · Brain and Behavior · 19

PDF

Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulans AFO-202 and N-163 produced beta glucans in Sprague Dawley rats

2021 · Nobunao Ikewaki, Kadalraja Raghavan, et al. · Clinical Immunology Communications · 17

PDF

Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study

2023 · Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, et al. · IBRO Neuroscience Reports · 15

PDF

Randomised trial of Aureobasidium pullulans -produced beta 1,3-1,6-glucans in patients with Duchenne muscular dystrophy: Favourable changes in gut microbiota and clinical outcomes indicating their potential in epigenetic manipulation

2022 · Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, et al. · medRxiv · 11

Beneficial Immune Regulation by Biological Response Modifier Glucans in COVID-19 and Their Envisaged Potentials in the Management of Sepsis

2022 · Senthilkumar Preethy, Kadalraja Raghavan, et al. · Frontiers in Immunology · 9

PDF

Integrating the Synergy of the Gut Microbiome into Regenerative Medicine: Relevance to Neurological Disorders

2022 · Senthilkumar Preethy, Natarajan Ranganathan, et al. · Journal of Alzheimer s Disease · 8

PDF

Improving the therapeutic efficacy of gene therapy for duchenne muscular dystrophy (DMD) by evaluating and managing inflammation

2025 · Kadalraja Raghavan, Nobunao Ikewaki, et al. · Frontiers in Genetics · 7

PDF

Potentials to alleviate coagulopathy and enhance microglial function of beta (β)- glucans, making them worth a clinical study for COVID-19's neurological sequalae

2021 · Kadalraja Raghavan, Ramesh Shankar Kandaswamy, et al. · Journal of the Neurological Sciences · 7

PDF

Enhanced expression of dystrophin, IGF-1, CD44 and MYH3 in plasma and skeletal muscles including diaphragm of mdx mice after oral administration of Neu REFIX beta 1,3-1,6 glucan

2025 · Senthilkumar Preethy, Shuji Sakamoto, et al. · Scientific Reports · 6

Efficient control of IL-6, CRP and Ferritin in Covid-19 patients with two variants of Beta-1,3-1,6 glucans in combination, within 15 days in an open-label prospective randomized clinical trial

2021 · Subramanian Pushkala, Sudha Seshayyan, et al. · medRxiv · 6

Efficacy of N-163 strain of Aureobasidium pullulans -produced beta-glucan in improving muscle strength and function in patients with Duchenne muscular dystrophy; Results of a 6-month non-randomised open-label linear clinical trial

2023 · Kadalraja Raghavan, Thanasekar Sivakumar, et al. · medRxiv · 5

PDF

Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory clinical study

2021 · Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, et al. · medRxiv · 5

PDF

Efficient Control of IL-6, CRP and Ferritin in COVID-19 Patients With Two Variants of Beta-1,3-1,6 Glucans in Combination: An Open-Label, Prospective, Randomised Clinical Trial

2025 · Subramanian Pushkala, Sudha Seshayyan, et al. · Global Advances in Integrative Medicine and Health · 4

Qualitative Evaluation of α-Synuclein: A Critical Step in Unravelling the Complexities of Autism Spectrum Disorder

2022 · Senthilkumar Preethy, Kadalraja Raghavan, et al. · Medical Principles and Practice · 4

Improvement of sleep patterns and serum melatonin levels in children with autism spectrum disorders after consumption of beta-1,3/1,6-glucan in a pilot clinical study

2021 · Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, et al. · Research Square · 4

PDF

Approaching α-synuclein misfolding through gut microbiome; strategies for the management of neurological conditions

2025 · Nobunao Ikewaki, Muralidhar L Hegde, et al. · Future Neurology · 3

PDF

Re-examination of therapeutic management of muscular dystrophies using a vascular smooth muscle-centered approach

2023 · Senthilkumar Preethy, Naoki Yamamoto, et al. · Journal of Smooth Muscle Research · 2

PDF

Corrigendum to “Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study” [IBRO Neurosci. Rep. 15 (2023), pp. 90–99]

2023 · Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, et al. · IBRO Neuroscience Reports · 1

PDF

Randomised trial of Aureobasidium pullulans-produced beta 1,3-1,6-glucans in patients with Duchenne muscular dystrophy: favourable changes in gut microbiota and clinical outcomes indicating their potential in epigenetic manipulation

2025 · Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, et al. · BMJ Nutrition Prevention & Health

PDF

Corrigendum to “Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulansAFO-202 and N-163 produced beta glucans in Sprague Dawley rats” [Clinical Immunology Communications 1 (2021) 29–34]

2024 · Nobunao Ikewaki, Kadalraja Raghavan, et al. · Clinical Immunology Communications

Works count: 30

Citation count: 299

H-index: 9

I10-index: 9